165 related articles for article (PubMed ID: 2258577)
21. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay.
Ahmann A; Baker JR; Weetman AP; Wartofsky L; Nutman TB; Burman KD
J Clin Endocrinol Metab; 1987 Mar; 64(3):454-60. PubMed ID: 2434519
[TBL] [Abstract][Full Text] [Related]
22. Graves' ophthalmopathy and tobacco smoking.
Tallstedt L; Lundell G; Taube A
Acta Endocrinol (Copenh); 1993 Aug; 129(2):147-50. PubMed ID: 8103953
[TBL] [Abstract][Full Text] [Related]
23. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
[TBL] [Abstract][Full Text] [Related]
25. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy.
Antonelli A; Saracino A; Alberti B; Canapicchi R; Cartei F; Lepri A; Laddaga M; Baschieri L
Acta Endocrinol (Copenh); 1992 Jan; 126(1):13-23. PubMed ID: 1736548
[TBL] [Abstract][Full Text] [Related]
26. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology.
Villanueva R; Inzerillo AM; Tomer Y; Barbesino G; Meltzer M; Concepcion ES; Greenberg DA; MacLaren N; Sun ZS; Zhang DM; Tucci S; Davies TF
Thyroid; 2000 Sep; 10(9):791-8. PubMed ID: 11041456
[TBL] [Abstract][Full Text] [Related]
27. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.
Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR
Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192
[TBL] [Abstract][Full Text] [Related]
29. HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.
Schleusener H; Schernthaner G; Mayr WR; Kotulla P; Bogner U; Finke R; Meinhold H; Koppenhagen K; Wenzel KW
J Clin Endocrinol Metab; 1983 Apr; 56(4):781-5. PubMed ID: 6131902
[TBL] [Abstract][Full Text] [Related]
30. Analysis of HLA-DQB and HLA-DPB alleles in Graves' disease by oligonucleotide probing of enzymatically amplified DNA.
Weetman AP; Zhang L; Webb S; Shine B
Clin Endocrinol (Oxf); 1990 Jul; 33(1):65-71. PubMed ID: 2401099
[TBL] [Abstract][Full Text] [Related]
31. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
Czaja AJ; Carpenter HA; Moore SB
Liver Int; 2006 Jun; 26(5):552-8. PubMed ID: 16761999
[TBL] [Abstract][Full Text] [Related]
32. Association of hypergammaglobulinemia G with HLA-DR3 in Graves' disease.
Briones-Urbina R; Bear JC; Farid NR
Tissue Antigens; 1982 Jan; 19(1):20-4. PubMed ID: 6896102
[TBL] [Abstract][Full Text] [Related]
33. Significance of HLA DR4 in type 1 autoimmune hepatitis.
Czaja AJ; Carpenter HA; Santrach PJ; Moore SB
Gastroenterology; 1993 Nov; 105(5):1502-7. PubMed ID: 8224654
[TBL] [Abstract][Full Text] [Related]
34. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
[TBL] [Abstract][Full Text] [Related]
35. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
36. E-rosette formation in Graves' ophthalmopathy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
[TBL] [Abstract][Full Text] [Related]
37. Serological and molecular studies of HLA in Sardinian patients with Graves' disease.
La Nasa G; Martino E; Carcassi C; Mulargia M; Floris L; Vacca A; Baldini G; Orrù S; Ledda A; Grasso L
Dis Markers; 1991; 9(6):307-12. PubMed ID: 1823309
[TBL] [Abstract][Full Text] [Related]
38. Graves' ophthalmopathy. A clinical and immunologic review.
Sergott RC; Glaser JS
Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
[TBL] [Abstract][Full Text] [Related]
39. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
Bartalena L; Marcocci C; Chiovato L; Laddaga M; Lepri G; Andreani D; Cavallacci G; Baschieri L; Pinchera A
J Clin Endocrinol Metab; 1983 Jun; 56(6):1139-44. PubMed ID: 6341388
[TBL] [Abstract][Full Text] [Related]
40. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.
Wiersinga WM; Smit T; van der Gaag R; Koornneef L
J Endocrinol Invest; 1988 Sep; 11(8):615-9. PubMed ID: 2907524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
